Turn Therapeutics Inc. (Nasdaq: TTRX) announced on September 10, 2026, that Chief Executive Officer Bradley Burnam and Executive Clinical and Regulatory Lead Stephen M. Hahn, M.D., will present at the Stifel 2026 Virtual Immunology and Inflammation Forum.
The presentation is scheduled for September 23, 2026, at 1:30 PM ET. The company stated that the presentation will provide a detailed look at its atopic dermatitis clinical program. This includes its pruritus-focused stage 2 enrichment strategy and emerging findings across distinct patient populations. These populations include patients with moderate-severe baseline pruritus, as well as a cohort characterized by lower EASI scores despite high investigator-assessed disease severity (IGA).
A live webcast of the presentation will be accessible on the Investors section of the Turn Therapeutics website. A replay of the webcast will be available on the website for approximately six months following the event.
Turn Therapeutics is a clinical-stage biotechnology company developing targeted, non-systemic therapies designed to act directly at the site of disease. Its lead therapeutic candidate, GX-03, is being evaluated in atopic dermatitis and is also being developed for onychomycosis.
